Completed
PHASE2
INTERVENTIONAL
NCT00047840
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
Interventions
Name:
ZD6474
Type:
DRUG
Description:
Name:
Placebo
Type:
DRUG
Description:
Name:
Docetaxel
Type:
DRUG
Description:
Primary Outcomes
Measure:
Outcome Progression free survival
TimeFrame:
Description:
Trial Information
NCT ID
NCT00047840
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Genzyme, a Sanofi Company
Last Updated
December 15, 2025